BLES

BLES

Manufacturer:

BLES Biochemicals

Distributor:

Averroes Pharma
Concise Prescribing Info
Contents
Bovine lipid extr surfactant
Indications/Uses
Rescue treatment of neonatal resp distress syndrome.
Dosage/Direction for Use
Recommended dose: 135 mg/kg as 3 subsequent doses w/in 1st 5 days of life.
Contraindications
Infants w/ active pulmonary haemorrhage.
Special Precautions
Intended for intratracheal use only. Discontinue use if transient episodes of bradycardia & decreased O2 saturation occur. Not recommended for slow drip or use of small test aliquots. Hyperoxia. Increased risk of sepsis. Mucous plug obstruction. Correct acidosis, hypotension, hypoglycemia & hypothermia prior to therapy. Monitor infants for oxygenation & blood gas measurements; tidal vol after dosing.
Adverse Reactions
Patent ductus arteriosus, decreased post-dose pulmonary function values, all grade intraventricular haemorrhage, sepsis, retinopathy of prematurity, bradycardia, severe intraventricular haemorrhage. Pulmonary interstitial emphysema, periventricular leukomalacia, pneumothorax, pulmonary haemorrhage, endotracheal tube complications, necrotizing enterocolitis, resp acidosis, convulsions, hypotension, apnoea, hydrocephalus, pneumonia.
ATC Classification
R07AA02 - natural phospholipids ; Belongs to the class of lung surfactants. Used in the treatment of respiratory diseases.
Presentation/Packing
Form
BLES Intratracheal susp 27 mg/mL
Packing/Price
3 mL x 1's;4 mL x 1's;5 mL x 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in